Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.45 |
| ▸ | TUBB | P07437 | 3/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.45 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28014269 | 0.98 | PTGS2 (0.46) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL4889037 | 0.97 | PTGS2 (0.47) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| Bromide SCHEMBL9088261 | 0.85 | KDM4E (0.36) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| Bromide SCHEMBL29880790 | 0.83 | LDHA (0.53) | MAPTSMN1; SMN2KMT2ASNCAABCB1 | |
| Bromide SCHEMBL4260842 | 0.83 | LDHA (0.53) | MAPTSMN1; SMN2KMT2ASNCAABCB1 | |
| Bromide SCHEMBL7436731 | 0.81 | TRAP1 (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30596298 | 0.81 | LDHA (0.54) | MAPTSMN1; SMN2KMT2ASNCAABCB1 | |
| Bromide SCHEMBL4365667 | 0.81 | ABCB1 (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Bromide SCHEMBL5440664 | 0.81 | SNCA (0.45) | SMN1; SMN2SNCA | |
| Hydrochloric Acid SCHEMBL4598739 | 0.80 | SNCA (0.41) | G6PDSMN1; SMN2MAPK1SNCAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501783-A | Erianin heterocyclic derivative and preparation method and application thereof | 上海应用技术大学 | 2021-10-15 | — | — | CN | claimed |
| CN-107382796-B | CA-4 antineoplastic medicine, synthetic method and application thereof | 浙江华理生物制药有限公司 | 2020-10-09 | — | — | CN | claimed |
| US-20200163913-A1 | CA-4 Antitumour Drug, Synthesis Method and Use Thereof | SHANGHAI HUALI BIOMEDICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | claimed |
| EP-4620466-A1 | TRIMETHOXYSTYRYL DERIVATIVES FOR USE IN THE TREATMENT OF PACLITAXEL-RESISTANT CANCER | Instituto de Investigación Biomédica de Salamanca De la Fundación Instituto Ciencia de la Salud De Castilla y León (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11497701-B2 | Multi-functional anti-microbial polymers and compositions containing same | CHEMGREEN INNOVATION INC. (CA) | 2022-11-15 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11279678-B2 | 5-fluorouracil derivatives, preparation methods and uses thereof | SHANGHAI ECUST BIOMEDICINE CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| CN-113501783-A | Erianin heterocyclic derivative and preparation method and application thereof | 上海应用技术大学 | 2021-10-15 | — | — | CN | disclosed |
| WO-2001012579-A2 | NEW STILBENES WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2001-02-22 | — | — | WO | disclosed |
| US-6162930-A | Anti-mitotic agents which inhibit tubulin polymerization | BAYLOR UNIVERSITY (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000048590-A1 | SUBSTITUTED STILBENE COMPOUNDS WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-08-24 | — | — | WO | disclosed |
| EP-0984954-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998039323-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5569786-A | ANTICARCINOGENIC AGENTS, LEUKEMIA | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5409953-A | Administering to treat lymphocytic leukemia | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0276051-B1 | ANTINEOPLASTIC COMPOUNDS | ARIZONA BOARD OF REGENTS (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0276051-A2 | Antineoplastic compounds | ARIZONA BOARD OF REGENTS (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | PTGS2 1385/4885TUBB4A 296/4885TUBB 213/4885 |
| US-11497701-B2 | Multi-functional anti-microbial polymers and compositions containing same | IPMK, ATIC, ARG1 | PTGS2 2838/4885TUBB4A 1244/4885TUBB 547/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PTGS2 1385/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PTGS2 1385/4885TUBB4A 296/4885TUBB 213/4885 |
| US-11279678-B2 | 5-fluorouracil derivatives, preparation methods and uses thereof | VEGFA, FLT4, FAU | PTGS2 1903/4885TUBB4A 208/4885TUBB 242/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | PTGS2 1385/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20200163913-A1 | CA-4 Antitumour Drug, Synthesis Method and Use Thereof | CA4, CA14, CA6 | PTGS2 3812/4885TUBB4A 8/4885TUBB 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.